Showing: 1 - 7 of 7 RESULTS
Briefing Full Analysis KetamineOne Capital Psychedelics

Ketamine One: Corporate Overview

KetamineOne Capital Ltd. (NEO: MEDI) is a Vancouver-based wellness company with a focus on becoming the North American leader in mental health treatments. The company is specifically driven to grow clinical offerings of ketamine-enhanced patient treatments and psilocybin-based psychedelic medicines, while building a vertically-integrated platform for the treatment of mental health issues. The company owns …

Briefing KetamineOne Capital News Psychedelics

KetamineOne Brings Scent-Enabled Virtual Reality To Psychedelic Therapy

KetamineOne Capital (NEO: MEDI) appears to be taking a rather novel approach to psychedelic treatments. The firm this morning revealed that it has signed an exclusive agreement to bring virtual reality to the treatment options the firm provides, with the tech further enhanced by providing an “olfactory-enabled” experience. The agreement itself is with that of …

Briefing KetamineOne Capital News Psychedelics

KetamineOne Sees CRO Subsidiary Apply For Controlled Substance Dealers License

KetamineOne Capital (NEO: MEDI) this morning announced that its wholly-owned subsidiary, KGK Science, has hit certain milestones related to expanding its service offerings. The expanded offerings relate to the firms psychedelic research capabilities as well as its expanded access to patients. The expanded research capabilities in the psychedelics space is related to a recently applied …

Adam Deffett Briefing Healthcare KetamineOne Capital Psychedelics The Daily Dive Video Series

Ketamine One: Developing A Network of Mental Health Clinics – The Daily Dive

Today on the Daily Dive, we are joined by Adam Deffett, VP of Capital Markets for KetamineOne Capital (NEO: MEDI). Adam, joins us this afternoon to discuss the strategy behind Ketamine One and how it relates to recent acquisitions, the move to the NEO exchange, IVR therapies, and the future of the ketamine space as …